Based on clinical evidence from large clinical trials (136–138), the current therapeutic strategy combines BRAF and MEK inhibition, including three FDA approved combinations for the treatment of metastatic BRAF-mut melanoma: dabrafenib plus trametinib, vemurafenib plus cobimetinib, and encorafenib plus binimetinib (Figure 5). This evidence concerns the gene BRAF and melanoma.